No Yes Ok

Archive

Newer Entries »

Agenus Announces Clearance of Investigational New Drug Applications by the FDA for anti-CTLA-4 and antiGITR Antibodies Thursday, January 21st, 2016
Clinical studies for both checkpoint modulator antibodies allowed to commence   LEXINGTON, Mass., January 21, 2016--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoin [...]
LSP’s portfolio company Kuros closes merger with Cytos and is now listed as Kuros Biosciences Ltd on Swiss stock exchange Wednesday, January 20th, 2016
Amsterdam, the Netherlands – 20 January 2016 – Our portfolio company Kuros Biosciences Ltd. (SIX:KURN formerly CYTN) (“Kuros”), a developer of innovative products for tissue repair and regeneration, today anno [...]
LSP Leads Financing Round in Insulin Pump Company ViCentra Wednesday, January 20th, 2016
Amsterdam, the Netherlands, 20 January 2016. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series B Round of ViCentra B.V., a private Dutch company commercia [...]
argenx announces € 16 M investment by US funds advised by subsidiaries of Federated Investors Tuesday, January 19th, 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBU [...]
Merus and Gustave Roussy Form Strategic Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Immuno-Oncology Applications Monday, January 4th, 2016
UTRECHT, The Netherlands and VILLEJUIF, France, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and Institut Gustave Rouss [...]

Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

Newer Entries »

Agenus Announces Clearance of Investigational New Drug Applications by the FDA for anti-CTLA-4 and antiGITR Antibodies Thursday, January 21st, 2016
Clinical studies for both checkpoint modulator antibodies allowed to commence   LEXINGTON, Mass., January 21, 2016--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoin [...]
LSP’s portfolio company Kuros closes merger with Cytos and is now listed as Kuros Biosciences Ltd on Swiss stock exchange Wednesday, January 20th, 2016
Amsterdam, the Netherlands – 20 January 2016 – Our portfolio company Kuros Biosciences Ltd. (SIX:KURN formerly CYTN) (“Kuros”), a developer of innovative products for tissue repair and regeneration, today anno [...]
LSP Leads Financing Round in Insulin Pump Company ViCentra Wednesday, January 20th, 2016
Amsterdam, the Netherlands, 20 January 2016. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series B Round of ViCentra B.V., a private Dutch company commercia [...]
argenx announces € 16 M investment by US funds advised by subsidiaries of Federated Investors Tuesday, January 19th, 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBU [...]
Merus and Gustave Roussy Form Strategic Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Immuno-Oncology Applications Monday, January 4th, 2016
UTRECHT, The Netherlands and VILLEJUIF, France, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and Institut Gustave Rouss [...]

Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund